期刊文献+

高效液相色谱法测定复方辛伐他汀烟酸缓释片的有关物质 被引量:1

Determination of the related substances in compound simvastatin and niacin extended-release tablets by HPLC
暂未订购
导出
摘要 目的建立复方辛伐他汀烟酸缓释片有关物质检查的HPLC方法。方法采用C18柱,以乙腈-0.1%磷酸溶液(50∶50)为流动相A,0.1%磷酸的乙腈溶液为流动相B,梯度洗脱,对辛伐他汀的有关物质进行检测;以乙腈-0.05mol·L-1磷酸二氢钠溶液(磷酸调pH至2.5)(1∶99)为流动相,对烟酸进行检测。结果在建立的色谱条件下,辛伐他汀、烟酸峰与其相关杂质峰均能完全分离。结论本法简便、准确、专属性强,可用于本品的有关物质检查。 OBJECTIVE To establish a HPLC methed for the determination of the related substances in com- pound simvastatin and niacin extended-release tablets. METHODS For the test of simvastatin, chromatography was carried out on a CIs column with mobile phase of A (acetonitrile-0.1% phosphoric acid, 50:50) and B (ace- tonitrile-phosphoric acid, 999:1) at the detection wavelength of 238nm by gradient program; For the analysis of niacin, chromatography was performed on a C18 column with mobile phase of acetonitrile-0.05mol· L- 1 sodium all- hydrogen phosphate solution (pH 2.5, adjusted by phosphoric acid) (1 : 99) at the detection wavelength of 262nm. RERUSTS Under the established conditions, simvastatin, niacin and their related substances were separat- ed completely, methods have been validated and the stability test under various conditions have been per- formed. CONCLUSION METHODS This is simple,accurate and sensitive. It can be used in the quality control of compound simvastatin and niacin extended-release tablets.
出处 《海峡药学》 2012年第6期34-36,共3页 Strait Pharmaceutical Journal
关键词 辛伐他汀 烟酸 有关物质 高效液相色谱法 Simvastatin Niacin Related substances HPLC
  • 相关文献

参考文献3

二级参考文献19

  • 1张玉琥.化学药物复方制剂杂质研究的特点及基本思路[J].中国新药杂志,2006,15(16):1327-1329. 被引量:11
  • 2ICH Harmonised Tripartite Guideline: Impurities In New, Drug Snbstanres, Q3A (R) [S]. 2002 -02 -07.
  • 3ICH Harmonised Tripartite Guideline: Impurities In New Drug Substances, Q3B (R) [S]. 2003 -02 -05.
  • 4Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Proloaged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study [ J ]. Vascul Health Risk Manag,2007 ,3( 4 ) :467 - 79.
  • 5Knopp R H, Paramsothy P, Atkinson B,Dowdy A. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk [ J ]. Am J Cardiol, 2008,101 (Suppl) :48B - 57B.
  • 6Peter Alagona Jr. Beyond LDL cholesterol : the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining afer statin therapy [ J ]. Am J Manag Care,2009,15 : $65 - $73.
  • 7Cziraky M J. The impact of residual CVD risk in the management care setting [ J ]. Am J Manag Care,2009,15 : S74 - S80.
  • 8Robinson J G. Manangement of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin [ J]. Vasc Health Risk Manag,2009,5:31 - 43.
  • 9Taylor A J,Villines T C, Stanek E J, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness [ J ]. N Engl J Med,2009,361:2113 - 22.
  • 10Lamon-Fava S, Diffenderfer M R, Barrett P H, et al. Extended-release niacin alters the metabolism of plasma Apolipoprotein(Apo) A-I and ApoB-containing lipoproteins[ J]. Arterioscler Thromb Vasc Biol,2008,28 : 1672 - 8.

共引文献29

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部